CPAP Effect on the Polycythemia in Patients With Obstructive Sleep Apnea
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Objectives: To compare the response of polycythemia in terms of hematocrit decrease in
patients treated with positive airway pressure (CPAP) versus patients not treated with CPAP.
Methodology: Randomized, parallel-group, nonblinded, controlled clinical trial.
Patients diagnosed with OSA in a respiratory polygraphy (RP) and who meet all the inclusion
criteria and none of the exclusion criteria will undergo sleepiness and quality of life
questionnaires, anthropometric measurements and blood tests and will be randomized to a CPAP
treatment group or control group, maintaining this treatment for 12 months. A visit will be
made at 12 weeks ,24 weeks and 52 weeks to check compliance with CPAP in the treatment group
and to carry out questionnaires on physical activity and quality of life, anthropometric
measurements, blood tests including hemoglobin and hematocrit as well as parameters related
to coagulation and platelet function and changes in medication as well as adverse effects.
Efficacy variables: blood count, hemoglobin, haematocrit, erythropoietin, mean corpuscular
volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration
(MCHC), mean platelet volume (MPV), platelets, coagulation, erythrocyte range of distribution
(ADE), glucose, creatinine, glomerular filtration rate, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), Total bilirubin, hypoxic
burden, Epworth score, EuroQol- 5D questionnaire.